Paclitaxel and ABI-007 in Treating Patients With Locally Advanced or Metastatic Solid Tumors

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00095914
Recruitment Status : Completed
First Posted : November 9, 2004
Last Update Posted : March 15, 2012
National Cancer Institute (NCI)
Information provided by:
National Institutes of Health Clinical Center (CC)

Brief Summary:

RATIONALE: Drugs used in chemotherapy, such as paclitaxel and ABI-007, work in different ways to stop tumor cells from dividing so they stop growing or die. Combining paclitaxel with ABI-007 may kill more tumor cells.

PURPOSE: Randomized phase I trial to study the effectiveness of combining paclitaxel with ABI-007 in treating patients who have locally advanced or metastatic solid tumors.

Condition or disease Intervention/treatment Phase
Unspecified Adult Solid Tumor, Protocol Specific Drug: paclitaxel Drug: paclitaxel albumin-stabilized nanoparticle formulation Phase 1

Detailed Description:



  • Determine whether a change in the formulation alters the pharmacokinetic profile of paclitaxel in the plasma of patients with incurable locally advanced or metastatic solid tumors treated with ABI-007 and paclitaxel.


  • Correlate pharmacokinetic data of this regimen with decrease in the neutrophil count at nadir in these patients.
  • Determine the intra- and interindividual pharmacokinetic variability of ABI-007 in these patients.
  • Determine protein binding of paclitaxel via measurement of α-1-acid glycoprotein and serum albumin levels in patients treated with this regimen.

OUTLINE: This is a randomized, pilot study.

  • Courses 1 and 2: Patients are randomized to 1 of 2 treatment arms.

    • Arm I: Patients receive paclitaxel IV over 3 hours on day 1 and ABI-007 IV over 30 minutes on day 22.
    • Arm II: Patients receive ABI-007 IV over 30 minutes on day 1 and paclitaxel IV over 3 hours on day 22.
  • Courses 3 and beyond: All patients receive ABI-007 IV over 30 minutes on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.

PROJECTED ACCRUAL: A total of 20 patients will be accrued for this study.

Study Type : Interventional  (Clinical Trial)
Primary Purpose: Treatment
Official Title: Randomized, Crossover, Pharmacokinetic Study Of Paclitaxel (Taxol) And ABI-007 (A Cremophor EL-Free, Protein Stabilized, Nanoparticle Paclitaxel) In Patients With Advanced Solid Tumors
Study Start Date : September 2004
Actual Primary Completion Date : May 2007
Actual Study Completion Date : March 2009

Resource links provided by the National Library of Medicine

Drug Information available for: Paclitaxel

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No


  • Histologically confirmed malignant solid tumor

    • Considered incurable
    • Locally advanced or metastatic disease
  • Likely to be responsive to taxane-based therapy

    • Patients who are refractory to prior paclitaxel are ineligible
  • No symptomatic or untreated brain metastasis or carcinomatous meningitis

    • No patients who are unable to remain free of corticosteroid therapy for > 4 weeks due to CNS disease
  • No previously untreated locally advanced breast cancer
  • No hematologic malignancy



  • 18 and over

Performance status

  • ECOG 0-2

Life expectancy

  • At least 3 months


  • Granulocyte count ≥ 1,500/mm^3
  • Platelet count ≥ 100,000/mm^3


  • Bilirubin normal
  • ALT and AST ≤ 1.5 times upper limit of normal


  • Creatinine normal OR
  • Creatinine clearance ≥ 60 mL/min


  • LVEF ≥ 40%
  • No clinical signs or symptoms of heart failure
  • No symptomatic congestive heart failure
  • No unstable angina pectoris


  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception during and for 2 months after study participation
  • No history of allergic reaction attributed to compounds of similar chemical or biologic composition to paclitaxel (e.g., docetaxel, Cremophor^® EL [CrEL], polysorbate 80 [Tween 80], or CrEL-containing medications [e.g., cyclosporine])
  • No history of seizure disorder requiring anticonvulsant therapy
  • No active serious infection
  • No psychiatric illness or social situation that would preclude study compliance
  • No other uncontrolled illness


Biologic therapy

  • No concurrent immunotherapy
  • No concurrent filgrastim (G-CSF) during courses 1 and 2


  • See Disease Characteristics
  • At least 3 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin)
  • No other concurrent chemotherapy

Endocrine therapy

  • See Disease Characteristics
  • At least 2 weeks since prior hormonal therapy
  • Concurrent luteinizing hormone-releasing hormone agonists for prostate cancer allowed


  • At least 3 weeks since prior radiotherapy
  • No concurrent radiotherapy


  • Not specified


  • More than 2 weeks since prior drugs, herbal preparations, or dietary supplements known to influence CYP3A4 (e.g., phenytoin, rifampin, Hypericum perforatum [St. John's wort], garlic supplements, or grapefruit juice) and/or CYP2C8
  • No concurrent substances known or likely to interfere with the pharmacokinetics of paclitaxel (e.g., verapamil or cyclosporine)
  • No other concurrent investigational agents
  • No other concurrent anticancer therapy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00095914

United States, Maryland
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support
Bethesda, Maryland, United States, 20892-1182
Sponsors and Collaborators
National Institutes of Health Clinical Center (CC)
National Cancer Institute (NCI)
Study Chair: William D. Figg, PharmD National Cancer Institute (NCI) Identifier: NCT00095914     History of Changes
Obsolete Identifiers: NCT00092261
Other Study ID Numbers: 040280
First Posted: November 9, 2004    Key Record Dates
Last Update Posted: March 15, 2012
Last Verified: March 2012

Keywords provided by National Institutes of Health Clinical Center (CC):
unspecified adult solid tumor, protocol specific

Additional relevant MeSH terms:
Albumin-Bound Paclitaxel
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action